Back to search results

Ravulizumab for Severe Preeclampsia in Pregnancy

Researchers are studying ravulizumab, an intravenous (IV) medication, for pregnant individuals with severe preeclampsia (a serious high blood pressure condition during pregnancy) or HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets – a severe form of preeclampsia). This study is looking at how ravulizumab affects certain markers in the blood related to the immune system (Alternative Complement Pathway Biomarkers) at the time of delivery. You may be able to join if you are a woman between 18 and 50 years old, less than 34 weeks pregnant, and have severe preeclampsia or HELLP features. The study aims to enroll 14 participants. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 14 participants. The phase of the study is not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures biomarkers at the time of delivery, which is measured at baseline.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06333652

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Recruiting
PHASE2Ages 18–50InterventionalTreatment
Mayo Clinic
~14 participants
Updated 2026-04-28 on ClinicalTrials.gov
What's tested:Ravulizumab

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Alternative Complement Pathway Biomarkers at time of delivery
Measured over Baseline

Conditions

Preeclampsia

Explore related trials

HELLP SyndromePreeclampsia

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Maria Lourdes Gonzalez Suarez, MD, PhD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Gonzalez Suarez
507-284-2511
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Individuals with \< 34 0/7 weeks of gestation.
Individuals with severe preeclampsia or HELLP features.

Exclusion

Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

What this trial measures

  • Alternative Complement Pathway Biomarkers at time of deliveryBaseline

    Concentration in serum of biomarkers: sMAC, Bb, and C5 at time of delivery